Beny Schmidt1, Tatiana Mesquita e Silva1, Cicília Yuko Wada2, Roberta Pessoa Simões3, Carina Mamy Nishimura3, Sabrina Telles Mathias Pupo3, Foued Salmen Espíndola4
1Unifesp – Universidade Federal de São Paulo – Department of Neuromuscular Diseases Investigation; 2 Statpharm Scientific Advisory Council; 3 Invel; 4 Probiotec Introduction
The studies’ onset with nitrogen oxide started in the 80s. In this period, the discovery of the nitric oxide (NO) as a molecular messenger for several mammalians systems revolutionized researches about its biological activity. This small and simple gaseous molecule, the NO, showed a crucial rule in early life-maintenance, the control of circulating platelets.
IGNARRO et al., 1987, also studied NO’s function In his Nobel prize winner’s study, he found out how the NO, the endothelium-derived relaxing factor (EDRF) released by endothelium cells from aorta artery, would respond along with hemoglobin to form the nitro hemoglobin.
FURCHGOTT researched the vasodilator factor associated to endothelium (EDRF), concluding years later that the NO is the responsible for its biological activity. He owned the Nobel Prize in Physiology and Medicine because of this research.
Vasodilators effects, produced by NO, are prevenient of its interaction with the soluble guanylate cyclase enzyme (sGC). The guanylate cyclase is a hemeprotein that catalyzes the conversion of guanosine triphosphate (GTP) to the second cyclic guanosine monophosphate (cGMP) messenger, and it is the action of such compound that addresses the relaxation of the smooth muscle.
Primary objective: To assess the ability of whether fabrics containing MIG3® Invel® Bioceramics produce the NO’s gasotransmitter through the nitrite quantification in the saliva in the BioC group, compared to C group.
Secondary objective: Supported by indexed publications, discuss about the action of the NO’s gasotransmitter in the human system, its’ benefits and its’ use in therapies.
An open-label, randomized, cross over study with two treatments, two periods (2 sequences), with a 7-days window between the periods, in which the research subjects received in each period treatment with BioC and C. 30 healthy male volunteers aged between 21 and 40 years old and with weight range of ±15% considering BMI between 19 and 25 Kg/m2. were included. The volunteer was required to present VO2max above 30mL.kg.min.
BioC Group – Invel® Actiive Shirt and Invel® Actiive Shorts.
C Group –“Hering®” cotton t-shirt and 100% Polyester shorts.
Samples Collection Time:
Saliva collection: Collection was performed using “Salivette®” collector:
Dose of Salivary Nitric Oxide: Nitrite levels in saliva were measured by Griess colorimetric assay (TSIKAS, 2005) and it was calculated from linear regression calculation, based on the values obtained from nitrite standard curve (NaNO2) with increasing concentrations ranging from 0.003 to 0.4 μM, where 50 μL of saliva were processed and incubated into 50 μL of Griess reagent. Reading was performed in a spectrophotometer at 570nm.
NO significant superiority of baseline BioC was seen compared to C. Estimation were: BioC: (71.65 ±5.77) and C: (47.76± 5.77). It was seen inferiority of baseline NO from period 1 compared to period 2. Estimations were P1: (51 ±5.77) and P2: (68.42± 5.77). Baseline NO means from sequence 1 and 2 were not significant. This indicates that research subjects randomization to sequences S1 (58.53 ±8.66) and S2 (60.88± 8.66) were properly performed.
Fabrics of MIG3® Invel® Bioceramics have the ability to promote NO’s gasotransmitter production and these are secure and effective fabrics. Thus, indications for the products manufactured with these fabrics are: Coadjutant treatments in the maintenance of blood flow, peripheral vasodilatation and regulation of local microcirculation. All these effects and its respective action mechanisms were well described by the authors and winners of Nobel prizes, Furchgott, 1999 and Ignarro et al., 1987. ANVISA, National Health Surveillance Agency, recognized the efficacy and safety of this product and granted on 13/JUN/2011 the register ANVISA/MS No. 80104760007.
1. FURCHGOTT, R. F. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci. Rep. v19, n.4, p. 235-251, Aug 1999.
2. IGNARRO, L. J.; BUGA, G. M.; WOOD, K. S.; BYRNS, R. E.; CHAUDHURI, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA. v.84, n.24, p.9265-9269, Dec 1987.
3. TSIKAS, D. Methods of quantitative analysis of the nitric oxide metabolites nitrite and nitrate in human biological fluids. Free Radic. Res. V.38, n.8, p.797-815, 2005.